Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TTNP | US
-0.21
-4.38%
Healthcare
Biotechnology
30/06/2024
21/10/2024
4.58
4.77
4.77
4.51
Titan Pharmaceuticals Inc. a pharmaceutical company develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States Canada and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco California.
View LessValue Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
42.0%1 month
48.4%3 months
216.8%6 months
165.3%-
-
1.10
-
-
-0.92
7.04
-
-7.09M
4.19M
4.19M
-
-237.63K
-
-100.00
-368.99
0.33
2.51
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.73
Range1M
1.17
Range3M
10.29
Rel. volume
1.22
Price X volume
62.60K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ADTX | ADTX | Biotechnology | 1.09 | 4.60M | 3.81% | n/a | 122.46% |
Pasithea Therapeutics Corp. Common Stock | KTTA | Biotechnology | 4.39 | 4.59M | 1.62% | n/a | 0.00% |
Hepion Pharmaceuticals Inc | HEPA | Biotechnology | 0.7501 | 4.35M | -8.30% | n/a | 4.33% |
AquaBounty Technologies Inc | AQB | Biotechnology | 1.1 | 4.25M | -8.33% | n/a | 10.41% |
NuCana plc | NCNA | Biotechnology | 1.86 | 4.18M | -1.06% | n/a | 0.00% |
Fresh America Corp | FRES | Biotechnology | 1.66 | 4.07M | -15.74% | n/a | 0.22% |
Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.4896 | 3.97M | -0.99% | n/a | 5.50% |
Windtree Therapeutics Inc | WINT | Biotechnology | 1.07 | 3.94M | 17.16% | n/a | 36.99% |
Genprex Inc | GNPX | Biotechnology | 1.51 | 3.91M | 265.62% | n/a | 0.00% |
InMed Pharmaceuticals Inc | INM | Biotechnology | 0.29 | 3.87M | 21.04% | n/a | 7.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.92 | 0.53 | Cheaper |
Ent. to Revenue | 7.04 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 1.10 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 216.78 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 4.19M | 3.66B | Emerging |